Reported 5 months ago
Eli Lilly has announced a commitment of over $5.3 billion to its Lebanon, Indiana manufacturing site, more than doubling its initial investment. This funding will allow the company to expand production of tirzepatide weight-loss and diabetes injections. Analysts and investors are pleased with this move, as it addresses the increasing demand for these drugs. Additionally, Goldman Sachs anticipates a $100 billion addressable market for this industry by 2030, with potential health benefits beyond weight management. Eli Lilly's investment is part of a broader trend of growth and innovation in the pharmaceutical industry.
Source: YAHOO